Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) has announced its adoption of Lantern Pharma's PredictBBB.ai platform, an artificial intelligence tool boasting 94% accuracy in predicting blood-brain barrier permeability. This strategic move aims to enhance Hoth's drug development process by leveraging AI technology to determine whether drug candidates can effectively cross the blood-brain barrier.
The partnership with Lantern Pharma's RADR® AI platform positions Hoth to potentially accelerate drug development timelines, reduce risks, and streamline candidate selection. The technology addresses a major challenge in drug development while potentially creating faster regulatory pathways and higher value inflection points for Hoth's pipeline.
Positive
- AI platform demonstrates high accuracy rate of 94% in blood-brain barrier permeability prediction
- Technology expected to reduce development risks and accelerate drug development timelines
- Potential for cost reduction in drug development process
- Strategic positioning for faster regulatory pathways
Negative
- None.
Insights
Hoth's adoption of Lantern's AI blood-brain barrier prediction platform could significantly accelerate CNS drug development and reduce costly failures.
Hoth Therapeutics' strategic adoption of Lantern Pharma's PredictBBB.ai platform represents a potentially significant advancement in their drug development capabilities. The platform's 94% accuracy in predicting blood-brain barrier (BBB) permeability addresses one of the most critical challenges in central nervous system (CNS) drug development. The blood-brain barrier historically functions as both a protective mechanism for the brain and a major obstacle for therapeutic delivery, with approximately 98% of small molecule drugs and nearly all large molecule therapeutics failing to penetrate this barrier effectively.
This AI implementation could substantially reduce development costs and timelines by enabling earlier elimination of non-viable candidates. Traditional methods of assessing BBB permeability rely on expensive and time-consuming in vitro and animal studies that often yield variable results. By front-loading this critical assessment through computational prediction, Hoth can prioritize molecules with higher probability of success before committing significant resources to their development.
For Hoth's pipeline, this technology may enable more efficient development of therapies targeting neurological conditions, potentially expanding their addressable markets. The focus on BBB permeability suggests Hoth may be strengthening or expanding their CNS portfolio, which would represent a strategic pipeline evolution. While the announcement doesn't specify financial terms, the implementation of AI-driven decision-making reflects an industry-wide shift toward computational approaches that reduce traditional R&D inefficiencies, positioning Hoth to potentially achieve development milestones with greater capital efficiency.
PredictBBB.ai, part of Lantern's RADR® AI platform, is a game-changing technology designed to eliminate one of the most significant bottlenecks in drug development: determining whether a candidate can cross the blood-brain barrier. By deploying this AI-driven solution, Hoth expects to streamline candidate selection, reduce development risk, and accelerate timelines toward transformative therapies.
"At Lantern Pharma, we're very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its
Strategic Impact for Hoth Therapeutics
The ability to cross the blood-brain barrier is a critical success factor for drug candidates. With PredictBBB.ai, Hoth gains access to AI-powered insights that increase precision and reduce uncertainty, potentially creating faster regulatory pathways and higher value inflection points for its pipeline.
"Hoth is committed to deploying disruptive technologies like AI to enhance precision in drug development," said Robb Knie, Chief Executive Officer Hoth Therapeutics. "Our integration of Lantern's PredictBBB.ai tool aligns with our mission to deliver life-changing therapies while driving efficiency, reducing costs, and unlocking new opportunities for patients and shareholders alike."
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-taps-lantern-pharmas-predictbbbai-platform--breakthrough-ai-with-94-accuracy-driving-next-gen-drug-development-302545700.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the accuracy rate of Lantern Pharma's PredictBBB.ai platform that Hoth Therapeutics (NASDAQ: HOTH) is adopting?
How will PredictBBB.ai benefit Hoth Therapeutics' drug development process?
What is the main challenge that PredictBBB.ai addresses in drug development?
Who are the key executives involved in the Hoth Therapeutics and Lantern Pharma collaboration?
What is the strategic impact of PredictBBB.ai for Hoth Therapeutics (HOTH)?
